metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	atezolizumab alone vs. gemcitabine plus platin	1	none	inconclusive results for: deaths (OS); objective responses (ORR); AE leading to death (grade 5); SAE (any grade); TRAE leading to death (grade 5); Asthenia TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Nausea TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4); Asthenia AE (grade 3-4); Hypertension AE (grade 3-4)	suggested 79 % decrease in DOR but the degree if certainty is unassessable suggested 86 % decrease in AE (any grade) but the degree if certainty is unassessable suggested 88 % decrease in AE (grade 3-4) but the degree if certainty is unassessable suggested 87 % decrease in AE leading to treatment discontinuation (any grade) but the degree if certainty is unassessable suggested 59 % decrease in STRAE (any grade) but the degree if certainty is unassessable suggested 93 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 96 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 93 % decrease in Anaemia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 97 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 92 % decrease in Thrombocytopenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 92 % decrease in Anaemia AE (grade 3-4) but the degree if certainty is unassessable suggested 78 % decrease in Fatigue AE (grade 3-4) but the degree if certainty is unassessable suggested 95 % decrease in Febrile neutropenia AE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Leucopenia AE (grade 3-4) but the degree if certainty is unassessable suggested 92 % decrease in Nausea AE (grade 3-4) but the degree if certainty is unassessable suggested 100 % decrease in Neutropenia AE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Thrombocytopenia AE (grade 3-4) but the degree if certainty is unassessable suggested 90 % decrease in Vomiting AE (grade 3-4) but the degree if certainty is unassessable	-
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	none	inconclusive results for: DOR; objective responses (ORR); AE (any grade); AE (grade 3-4); AE leading to death (grade 5); AE leading to treatment discontinuation (any grade); SAE (any grade); STRAE (any grade); TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); Anaemia TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Nausea TRAE (grade 3-4); Neutropenia TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4); Thrombocytopenia TRAE (grade 3-4); Anaemia AE (grade 3-4); Asthenia AE (grade 3-4); Fatigue AE (grade 3-4); Febrile neutropenia AE (grade 3-4); Hypertension AE (grade 3-4); Leucopenia AE (grade 3-4); Nausea AE (grade 3-4); Neutropenia AE (grade 3-4); Thrombocytopenia AE (grade 3-4); Vomiting AE (grade 3-4)	suggested 17 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 18 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 96 % increase in CRR but the degree if certainty is unassessable	-
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: progression or deaths (PFS); objective responses (ORR); AE (grade 3-4); AE leading to death (grade 5); SAE (any grade); TRAE leading to death (grade 5)	suggested 15 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 18 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable suggested 84 % decrease in DOR but the degree if certainty is unassessable suggested 62 % decrease in AE (any grade) but the degree if certainty is unassessable suggested 63 % decrease in AE leading to treatment discontinuation (any grade) but the degree if certainty is unassessable suggested 44 % decrease in STRAE (any grade) but the degree if certainty is unassessable suggested 72 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 67 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 78 % decrease in TRAE leading to discontinuation (any grade) but the degree if certainty is unassessable suggested 60 % decrease in Anaemia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 58 % decrease in Asthenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Constipation TRAE (grade 3-4) but the degree if certainty is unassessable suggested 63 % decrease in Fatigue TRAE (grade 3-4) but the degree if certainty is unassessable suggested 96 % decrease in Febrile neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 96 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 88 % decrease in Peripheral neuropathy TRAE (grade 3-4) but the degree if certainty is unassessable	-
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	2	none	inconclusive results for: deaths (OS); deaths (OS) (extension); progression or deaths (PFS); objective responses (ORR); AE (any grade); AE (grade 3-4); AE leading to death (grade 5); SAE (any grade); STRAE (any grade); TRAE leading to death (grade 5); Anaemia TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Constipation TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Febrile neutropenia TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4)	suggested 80 % decrease in DOR but the degree if certainty is unassessable suggested 56 % decrease in AE leading to treatment discontinuation (any grade) but the degree if certainty is unassessable suggested 62 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 45 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 63 % decrease in TRAE leading to discontinuation (any grade) but the degree if certainty is unassessable suggested 80 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable	-
mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population
mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive
MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population
versus no additional treatment
	atezolizumab alone vs. no additional treatment	1	none	-	-	-
MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive